id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-255037-i9guxtix	Reda, Gianluigi	Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy Hematology Network (REL)	2020-08-04		.txt	text/plain	1177	62	40	The authors also refer to the recent recommendations for the management of cancer patients in COVID era published by the EHA Infectious Disease Scientific Working Group Executive Committee. On the one hand, CLL is associated with a disease-related disruption of both humoral and cell-mediated immunity, on the other hand, patient-related factors such as age, disease stage, and type of treatment received play an important role [6] . Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (Btk) currently represents a milestone in the treatment of CLL and has been approved by FDA for the treatment of several B-cell malignancies and chronic graft-versus-host disease (cGVHD). Among 2902 CLL patients, 23 cases of COVID infections have been reported with molecular testing for SARS-CoV-2. In addition to its role on Btk, ibrutinib shows off-target inhibiting activity on IL-2-inducible T-cell kinase (Itk) and is thus capable of rebalancing the disease-inherent Th1/Th2 unbalance toward a Th1 phenotype in CLL patients. CLL and COVID-19 at the hospital clinic of Barcelona: an interim report	./cache/cord-255037-i9guxtix.txt	./txt/cord-255037-i9guxtix.txt